ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.14|
|52 Week High||AU$0.078|
|52 Week Low||AU$0.18|
|1 Month Change||31.82%|
|3 Month Change||38.10%|
|1 Year Change||79.01%|
|3 Year Change||-67.05%|
|5 Year Change||-91.21%|
|Change since IPO||-82.94%|
Recent News & Updates
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|IPD||AU Medical Equipment||AU Market|
Return vs Industry: IPD exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: IPD exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: IPD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: IPD's weekly volatility (9%) has been stable over the past year.
About the Company
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics.
ImpediMed Fundamentals Summary
|IPD fundamental statistics|
Is IPD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IPD income statement (TTM)|
|Cost of Revenue||AU$1.60m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.014|
|Net Profit Margin||-246.24%|
How did IPD perform over the long term?See historical performance and comparison
Is ImpediMed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: IPD (A$0.15) is trading above our estimate of fair value (A$0.13)
Significantly Below Fair Value: IPD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IPD is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: IPD is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IPD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IPD is overvalued based on its PB Ratio (8.5x) compared to the AU Medical Equipment industry average (4.5x).
How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: IPD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IPD's is expected to become profitable in the next 3 years.
Revenue vs Market: IPD's revenue (44.8% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: IPD's revenue (44.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPD's Return on Equity is forecast to be low in 3 years time (8.3%).
How has ImpediMed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPD is currently unprofitable.
Growing Profit Margin: IPD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: IPD has a negative Return on Equity (-81.16%), as it is currently unprofitable.
How is ImpediMed's financial position?
Financial Position Analysis
Short Term Liabilities: IPD's short term assets (A$25.7M) exceed its short term liabilities (A$8.1M).
Long Term Liabilities: IPD's short term assets (A$25.7M) exceed its long term liabilities (A$557.0K).
Debt to Equity History and Analysis
Debt Level: IPD is debt free.
Reducing Debt: IPD has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IPD has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 0.5% each year.
What is ImpediMed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IPD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and joined as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon has e...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD1.51M) is above average for companies of similar size in the Australian market ($USD556.28K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
Experienced Management: IPD's management team is seasoned and experienced (5 years average tenure).
Experienced Board: IPD's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.
ImpediMed Limited's employee growth, exchange listings and data sources
- Name: ImpediMed Limited
- Ticker: IPD
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$217.080m
- Shares outstanding: 1.50b
- Website: https://www.impedimed.com
Number of Employees
- ImpediMed Limited
- 50 Parker Court
- Unit 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.